2024-03-07 22:15:54
– A preventive treatment that is 90% effective once morest hospitalization
Nirsevimab, which works via an injection of an antibody, aims to immunize infants once morest respiratory syncytial virus (RSV). It would be 90% effective.
Published today at 11:15 p.m. Updated 40 minutes ago
Image d’illustration.
AFP
A preventive treatment once morest bronchiolitis, recently authorized, was 90% effective in protecting infants from hospitalization during this epidemic season in the United States, American health authorities announced Thursday.
The treatment in question, nirsevimab, works via the injection of an antibody, aimed at immunizing infants once morest the respiratory syncytial virus (RSV), responsible for bronchiolitis. It has been recommended since this summer in the United States for babies under 8 months going through their first season of exposure to RSV, if their mother was not vaccinated during her pregnancy.
The data released Thursday by the Centers for Disease Control and Prevention (CDC) are the first to provide an estimate of the treatment’s effectiveness in the United States, where RSV is the leading cause of infant hospitalization.
Vaccine
The study involved 685 babies between October 2023 and February 2024 (an entire epidemic season generally extends from October to March, specify the health authorities).
“Results show that nirsevimab was 90% effective in preventing RSV-related hospitalizations in infants during their first RSV season,” the CDC wrote. They clarified that the effectiveness of nirsevimab (Sanofi/AstraZeneca) might however be less over an entire season, which they plan to study subsequently.
American health authorities this summer also approved a Pfizer bronchiolitis vaccine, administered to pregnant women between 32 and 36 weeks of pregnancy, with the aim of protecting babies thanks to antibodies transmitted by the mother.
Did you find an error? Please report it to us.
0 comments
1709852217
#Bronchiolitis #preventive #treatment #effective #hospitalization
